Background: Early detection of disease allows for more treatment options and often results in better outcomes. Canine cancer is unfortunately a disease that can stay well hidden for a long time before becoming clinically evident, far into development. The Cancer Risk Assessment™ (CRA) is a blood test to screen apparently healthy dogs for early signs […] Read more »
Biomarker for Cancer Clinical Applications and Research We’re excited to bring you the newest Growing Body of Evidence: Thymidine Kinase. Research in support of TK1 as a biomarker for cancer detection and monitoring continues to mount. The Growing Body of Evidence provides a summary of that research, and applications for use in your practice. Click […] Read more »
As tumors advance they become more poorly differentiated. This results in a higher rate of incomplete cell cycle replication (dysregulated replication), higher tumor burden, and a higher rate of cell growth. All three of these factors increase TK1 levels substantially. Further, since inflammation is a functional part of tumor metastasis, cCRP also increases. Together, they […] Read more »
Published in the Journal of Veterinary Internal Medicine, Selting et al. examined the use of thymidine kinase, type 1 (TK1) and canine specific C-reactive protein (cCRP) in a wide range of hematological and solid tumors. There were 253 tumor-bearing dogs and 156 without cancer. Cancer: Dysregulated Proliferation TK1, an enzyme responsible for the production of thymidine […] Read more »
